source
- Eyepoint's wet AMD therapy misses primary goal in Phase 3, stock tumblesEyepoint reported that its experimental drug Duravyu did not keep vision in patients with wet age-related macular degeneration when given less frequently than the standard of care, causing the Phas…
- AstraZeneca reports positive late-stage results for Tagrisso-Orpathys combo and Enhertu in lung cancerAstraZeneca said on Monday that two separate late-stage studies in lung cancer have produced positive outcomes. One study evaluated a combination of the tyrosine-kinase inhibitor Tagrisso with the…